Cargando…
Biomaterial‐based gene therapy
Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239531/ https://www.ncbi.nlm.nih.gov/pubmed/37284583 http://dx.doi.org/10.1002/mco2.259 |
_version_ | 1785053506651029504 |
---|---|
author | Yu, Yi Gao, Yijun He, Liming Fang, Bairong Ge, Wenhui Yang, Pu Ju, Yikun Xie, Xiaoyan Lei, Lanjie |
author_facet | Yu, Yi Gao, Yijun He, Liming Fang, Bairong Ge, Wenhui Yang, Pu Ju, Yikun Xie, Xiaoyan Lei, Lanjie |
author_sort | Yu, Yi |
collection | PubMed |
description | Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the target cells due to their easy degradation in vivo and the structure of the target cell membranes. The introduction of genes into biological cells is often dependent on gene delivery vectors, such as adenoviral vectors, which are commonly used in gene therapy. However, traditional viral vectors have strong immunogenicity while also presenting a potential infection risk. Recently, biomaterials have attracted attention for use as efficient gene delivery vehicles, because they can avoid the drawbacks associated with viral vectors. Biomaterials can improve the biological stability of nucleic acids and the efficiency of intracellular gene delivery. This review is focused on biomaterial‐based delivery systems in gene therapy and disease treatment. Herein, we review the recent developments and modalities of gene therapy. Additionally, we discuss nucleic acid delivery strategies, with a focus on biomaterial‐based gene delivery systems. Furthermore, the current applications of biomaterial‐based gene therapy are summarized. |
format | Online Article Text |
id | pubmed-10239531 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-102395312023-06-05 Biomaterial‐based gene therapy Yu, Yi Gao, Yijun He, Liming Fang, Bairong Ge, Wenhui Yang, Pu Ju, Yikun Xie, Xiaoyan Lei, Lanjie MedComm (2020) Reviews Gene therapy, a medical approach that involves the correction or replacement of defective and abnormal genes, plays an essential role in the treatment of complex and refractory diseases, such as hereditary diseases, cancer, and rheumatic immune diseases. Nucleic acids alone do not easily enter the target cells due to their easy degradation in vivo and the structure of the target cell membranes. The introduction of genes into biological cells is often dependent on gene delivery vectors, such as adenoviral vectors, which are commonly used in gene therapy. However, traditional viral vectors have strong immunogenicity while also presenting a potential infection risk. Recently, biomaterials have attracted attention for use as efficient gene delivery vehicles, because they can avoid the drawbacks associated with viral vectors. Biomaterials can improve the biological stability of nucleic acids and the efficiency of intracellular gene delivery. This review is focused on biomaterial‐based delivery systems in gene therapy and disease treatment. Herein, we review the recent developments and modalities of gene therapy. Additionally, we discuss nucleic acid delivery strategies, with a focus on biomaterial‐based gene delivery systems. Furthermore, the current applications of biomaterial‐based gene therapy are summarized. John Wiley and Sons Inc. 2023-06-03 /pmc/articles/PMC10239531/ /pubmed/37284583 http://dx.doi.org/10.1002/mco2.259 Text en © 2023 The Authors. MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Reviews Yu, Yi Gao, Yijun He, Liming Fang, Bairong Ge, Wenhui Yang, Pu Ju, Yikun Xie, Xiaoyan Lei, Lanjie Biomaterial‐based gene therapy |
title | Biomaterial‐based gene therapy |
title_full | Biomaterial‐based gene therapy |
title_fullStr | Biomaterial‐based gene therapy |
title_full_unstemmed | Biomaterial‐based gene therapy |
title_short | Biomaterial‐based gene therapy |
title_sort | biomaterial‐based gene therapy |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10239531/ https://www.ncbi.nlm.nih.gov/pubmed/37284583 http://dx.doi.org/10.1002/mco2.259 |
work_keys_str_mv | AT yuyi biomaterialbasedgenetherapy AT gaoyijun biomaterialbasedgenetherapy AT heliming biomaterialbasedgenetherapy AT fangbairong biomaterialbasedgenetherapy AT gewenhui biomaterialbasedgenetherapy AT yangpu biomaterialbasedgenetherapy AT juyikun biomaterialbasedgenetherapy AT xiexiaoyan biomaterialbasedgenetherapy AT leilanjie biomaterialbasedgenetherapy |